{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T06:11:32Z","timestamp":1769235092582,"version":"3.49.0"},"reference-count":22,"publisher":"American Society of Hematology","issue":"17","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2012,4,26]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:p>Tyrosine kinase inhibitors (TKIs) and reduced intensity conditioning (RIC)\/nonmyeloablative (NMA) conditioning hematopoietic cell transplants (HCTs) have changed the therapeutic strategy for chronic myelogenous leukemia (CML) patients. We analyzed post-HCT outcomes of 306 CML patients reported to the Center for International Blood and Marrow Transplant Research aged 40 years and older undergoing RIC\/NMA HCT from 2001 to 2007: 117 (38%) aged 40 to 49 years, 119 (39%) 50 to 59 years, and 70 (23%) 60 years or older. The majority (74%) had treatment with imatinib before HCT. At HCT, most patients aged 40 to 49 years were in chronic phase (CP) 1 (74%), compared with 31% aged 60 years or older. Siblings were donors for 56% aged 40 to 49 years; older cohorts had more unrelated donors. The majority received peripheral blood grafts and RIC across all age groups. 3 year overall survival (54%, 52%, and 41%), day + 100 grade II-IV acute GVHD (26%, 32%, and 32%), chronic GVHD (58%, 51%, and 43%), and 1-year treatment-related mortality (18%, 20%, and 13%) were similar across ages. The 3-year relapse incidence (36%, 43%, and 66%) and disease-free survival (35%, 32%, and 16%) were inferior in the oldest cohort. Importantly, for CP1 patients, relapse and disease-free survival were similar across age cohorts. Allogeneic RIC HCT for older patients with CML can control relapse with acceptable toxicity and survival in TKI-exposed CML, especially if still in CP1.<\/jats:p>","DOI":"10.1182\/blood-2012-02-409763","type":"journal-article","created":{"date-parts":[[2012,3,10]],"date-time":"2012-03-10T19:06:06Z","timestamp":1331406366000},"page":"4083-4090","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":44,"title":["Reduced intensity conditioning is superior to nonmyeloablative conditioning for older chronic myelogenous leukemia patients undergoing hematopoietic cell transplant during the tyrosine kinase inhibitor era"],"prefix":"10.1182","volume":"119","author":[{"given":"Erica","family":"Warlick","sequence":"first","affiliation":[{"name":"Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kwang Woo","family":"Ahn","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Milwaukee, WI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tanya L.","family":"Pedersen","sequence":"additional","affiliation":[{"name":"Center for International Blood and Marrow Transplant Research, Minneapolis, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrew","family":"Artz","sequence":"additional","affiliation":[{"name":"University of Chicago Medical Center, Chicago, IL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marcos","family":"de Lima","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center, Houston, TX;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Michael","family":"Pulsipher","sequence":"additional","affiliation":[{"name":"Utah Blood & Marrow Transplant Program, Salt Lake City, UT;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gorgun","family":"Akpek","sequence":"additional","affiliation":[{"name":"Greenebaum Cancer Center, University of Maryland, Baltimore, MD;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mahmoud","family":"Aljurf","sequence":"additional","affiliation":[{"name":"King Faisal Specialist Hospital & Research Center, Riyadh, Saudi Arabia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Yves","family":"Cahn","sequence":"additional","affiliation":[{"name":"H\u00f4pital Albert Michallon, Centre Hospitalier Universitaire de Grenoble, Grenoble, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mitchell","family":"Cairo","sequence":"additional","affiliation":[{"name":"New York Presbyterian Hospital, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yi-Bin","family":"Chen","sequence":"additional","affiliation":[{"name":"Massachusetts General Hospital, Boston, MA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brenda","family":"Cooper","sequence":"additional","affiliation":[{"name":"University Hospitals Case Medical Center, Cleveland, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Abhinav","family":"Deol","sequence":"additional","affiliation":[{"name":"Karmanos Cancer Institute, Wayne State University, Detroit, MI;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sergio","family":"Giralt","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vikas","family":"Gupta","sequence":"additional","affiliation":[{"name":"Princess Margaret Hospital, Toronto, ON;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"H. Jean","family":"Khoury","sequence":"additional","affiliation":[{"name":"Emory University Hospital, Atlanta, GA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Holbrook","family":"Kohrt","sequence":"additional","affiliation":[{"name":"Stanford Hospital & Clinics, Stanford University Medical Center, Santa Clara, CA;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hillard M.","family":"Lazarus","sequence":"additional","affiliation":[{"name":"University Hospitals Case Medical Center, Cleveland, OH;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ian","family":"Lewis","sequence":"additional","affiliation":[{"name":"Royal Adelaide Hospital\/SA Pathology, Adelaide, Australia;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard","family":"Olsson","sequence":"additional","affiliation":[{"name":"Karolinska University Hospital, Stockholm, Sweden;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Joseph","family":"Pidala","sequence":"additional","affiliation":[{"name":"H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bipin N.","family":"Savani","sequence":"additional","affiliation":[{"name":"Vanderbilt University Medical Center, Brentwood, TN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthew","family":"Seftel","sequence":"additional","affiliation":[{"name":"CancerCare Manitoba\/University of Manitoba, Winnipeg, MB;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Gerard","family":"Soci\u00e9","sequence":"additional","affiliation":[{"name":"H\u00f4pital Saint-Louis, Paris, France;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Tallman","sequence":"additional","affiliation":[{"name":"Memorial Sloan-Kettering Cancer Center, New York, NY;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Celaettin","family":"Ustun","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ravi","family":"Vij","sequence":"additional","affiliation":[{"name":"Barnes Jewish Hospital, St Louis, MO; and"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lars","family":"Vindel\u00f8v","sequence":"additional","affiliation":[{"name":"Rigshopitalet, Copenhagen, Denmark"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Daniel","family":"Weisdorf","sequence":"additional","affiliation":[{"name":"Division of Hematology, Oncology, and Transplant, University of Minnesota, Minneapolis, MN;"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"issue":"6","key":"2019111808162339500_B1","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1182\/blood.V99.6.1971","article-title":"Allogeneic bone marrow transplantation for chronic myelogenous leukemia: comparative analysis of unrelated versus matched sibling donor transplantation.","volume":"99","author":"Weisdorf","year":"2002","journal-title":"Blood"},{"issue":"5","key":"2019111808162339500_B2","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1182\/blood-2006-02-001495","article-title":"Survival advantage from imatinib compared with the combination interferon-alpha plus cytarabine in chronic-phase chronic myelogenous leukemia: historical comparison between two phase 3 trials.","volume":"108","author":"Roy","year":"2006","journal-title":"Blood"},{"issue":"6","key":"2019111808162339500_B3","doi-asserted-by":"crossref","first-page":"1054","DOI":"10.1038\/leu.2009.38","article-title":"Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"issue":"24","key":"2019111808162339500_B4","doi-asserted-by":"crossref","first-page":"2260","DOI":"10.1056\/NEJMoa1002315","article-title":"Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia.","volume":"362","author":"Kantarjian","year":"2010","journal-title":"N Engl J Med"},{"issue":"24","key":"2019111808162339500_B5","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1056\/NEJMoa0912614","article-title":"Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia.","volume":"362","author":"Saglio","year":"2010","journal-title":"N Engl J Med"},{"issue":"7","key":"2019111808162339500_B6","doi-asserted-by":"crossref","first-page":"748","DOI":"10.1016\/j.bbmt.2008.04.003","article-title":"Classification of HLA-matching for retrospective analysis of unrelated donor transplantation: revised definitions to predict survival.","volume":"14","author":"Weisdorf","year":"2008","journal-title":"Biol Blood Marrow Transplant"},{"issue":"7","key":"2019111808162339500_B7","doi-asserted-by":"crossref","first-page":"844","DOI":"10.1016\/j.bbmt.2007.03.011","article-title":"Reduced-intensity conditioning for unrelated donor progenitor cell transplantation: long-term follow-up of the first 285 reported to the National Marrow Donor Program.","volume":"13","author":"Giralt","year":"2007","journal-title":"Biol Blood Marrow Transplant"},{"issue":"12","key":"2019111808162339500_B8","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1016\/j.bbmt.2009.07.004","article-title":"Defining the intensity of conditioning regimens: working definitions.","volume":"15","author":"Bacigalupo","year":"2009","journal-title":"Biol Blood Marrow Transplant"},{"issue":"1","key":"2019111808162339500_B9","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1046\/j.1365-2141.2000.02196.x","article-title":"Harnessing graft-versus-malignancy: non-myeloablative preparative regimens for allogeneic haematopoietic transplantation, an evolving strategy for adoptive immunotherapy.","volume":"111","author":"Champlin","year":"2000","journal-title":"Br J Haematol"},{"issue":"6","key":"2019111808162339500_B10","first-page":"825","article-title":"1994 Consensus Conference on Acute GVHD Grading.","volume":"15","author":"Przepiorka","year":"1995","journal-title":"Bone Marrow Transplant"},{"issue":"15","key":"2019111808162339500_B11","doi-asserted-by":"crossref","first-page":"4242","DOI":"10.1182\/blood-2011-03-344390","article-title":"Global and organ-specific chronic graft-versus-host disease severity according to the 2005 NIH Consensus Criteria.","volume":"118","author":"Arai","year":"2011","journal-title":"Blood"},{"key":"2019111808162339500_B12","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1080\/01621459.1958.10501452","article-title":"Nonparametric estimation from incomplete observations.","volume":"53","author":"Kaplan","year":"1958","journal-title":"J Am Stat Assoc"},{"issue":"10","key":"2019111808162339500_B13","doi-asserted-by":"crossref","first-page":"1880","DOI":"10.1182\/blood-2009-08-237115","article-title":"Allogeneic hematopoietic stem cell transplantation (allo SCT) for chronic myeloid leukemia in the imatinib era: evaluation of its impact within a subgroup of the randomized German CML Study IV.","volume":"115","author":"Saussele","year":"2010","journal-title":"Blood"},{"issue":"9","key":"2019111808162339500_B14","doi-asserted-by":"crossref","first-page":"1628","DOI":"10.1038\/leu.2009.156","article-title":"Dasatinib-associated major molecular responses in patients with chronic myeloid leukemia in chronic phase following imatinib failure: response dynamics and predictive value.","volume":"23","author":"Hochhaus","year":"2009","journal-title":"Leukemia"},{"key":"2019111808162339500_B15","article-title":"Nilotinib in patients with Ph+ chronic myeloid leukemia in accelerated phase following imatinib resistance or intolerance: 24-month follow-up results [published online ahead of print, November 11, 2011].","author":"le Coutre","journal-title":"Leukemia"},{"issue":"1","key":"2019111808162339500_B16","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1002\/cncr.26249","article-title":"Expanding Nilotinib Access in Clinical Trials (ENACT): an open-label, multicenter study of oral nilotinib in adult patients with imatinib-resistant or imatinib-intolerant Philadelphia chromosome-positive chronic myeloid leukemia in the chronic phase.","volume":"118","author":"Nicolini","year":"2012","journal-title":"Cancer"},{"issue":"4","key":"2019111808162339500_B17","doi-asserted-by":"crossref","first-page":"583","DOI":"10.3109\/10428191003637282","article-title":"Dasatinib and nilotinib in imatinib-resistant Philadelphia-positive chronic myelogenous leukemia: a \u2018head-to-head comparison\u2019.","volume":"51","author":"Rosti","year":"2010","journal-title":"Leuk Lymphoma"},{"issue":"3","key":"2019111808162339500_B18","doi-asserted-by":"crossref","first-page":"232","DOI":"10.1200\/JCO.2011.38.6565","article-title":"Assessment of BCR-ABL1 transcript levels at 3 months is the only requirement for predicting outcome for patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors.","volume":"30","author":"Marin","year":"2012","journal-title":"J Clin Oncol"},{"issue":"3","key":"2019111808162339500_B19","doi-asserted-by":"crossref","first-page":"3641","DOI":"10.1182\/blood-2010-08-302679","article-title":"Results of allogeneic hematopoietic stem cell transplantation for chronic myelogenous leukemia patients who failed tyrosine kinase inhibitors after developing BCR-ABL1 kinase domain mutations.","volume":"117","author":"Jabbour","year":"2011","journal-title":"Blood"},{"issue":"4","key":"2019111808162339500_B20","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.1182\/blood-2006-02-001933","article-title":"Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.","volume":"108","author":"Jabbour","year":"2006","journal-title":"Blood"},{"issue":"15","key":"2019111808162339500_B21","doi-asserted-by":"crossref","first-page":"3631","DOI":"10.1002\/cncr.25092","article-title":"Stem cell transplantation for patients with chronic myeloid leukemia resistant to tyrosine kinase inhibitors with BCR-ABL kinase domain mutation T315I.","volume":"116","author":"Velev","year":"2010","journal-title":"Cancer"},{"issue":"20","key":"2019111808162339500_B22","doi-asserted-by":"crossref","first-page":"5697","DOI":"10.1182\/blood-2011-07-367326","article-title":"Allogeneic stem cell transplantation for patients harboring T315I BCR-ABL mutated leukemias.","volume":"118","author":"Nicolini","year":"2011","journal-title":"Blood"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/17\/4083\/1351199\/zh801712004083.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/blood\/article-pdf\/119\/17\/4083\/1351199\/zh801712004083.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2019,11,18]],"date-time":"2019-11-18T13:36:32Z","timestamp":1574084192000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/119\/17\/4083\/29876\/Reduced-intensity-conditioning-is-superior-to"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,4,26]]},"references-count":22,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2012,4,26]]}},"URL":"https:\/\/doi.org\/10.1182\/blood-2012-02-409763","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,4,26]]}}}